Heinz Wiendl

Comment on "Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse".

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis.

A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape.

An autoreactive gamma delta TCR derived from a polymyositis lesion.

Advances in pathogenic concepts and therapeutic agents in Rasmussen's encephalitis.

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.

The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy.

Acute transverse myelitis associated with coxiella burnetii infection.

Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.

Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies.

Human herpesvirus 6 in serum and spinal fluid of patients with multiple sclerosis?

Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies.

The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis.

Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies.

Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes.

Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies.

Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo.

Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis.

Modulation of neuronal activity by the endogenous pentapeptide QYNAD.

A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation.

Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells.

Cathepsin G, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human B lymphocytes.

Antigen recognition properties of a Vgamma1.3Vdelta2-T-cell receptor from a rare variant of polymyositis.

Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.

Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.

Diffusion abnormality in Balo's concentric sclerosis: clues for the pathogenesis.

Localization of UDP-GlcNAc 2-epimerase/ManAc kinase (GNE) in the Golgi complex and the nucleus of mammalian cells.

Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS.

Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system.

A PD-1 polymorphism is associated with disease progression in multiple sclerosis.

Immunobiology of muscle: advances in understanding an immunological microenvironment.

Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.

Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.

Muscle-derived positive and negative regulators of the immune response.

Acute disseminated encephalomyelitis: an update.

Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands.

Multiple sclerosis: advances, excitements, disenchantments.

The contribution of TWIK-related acid-sensitive K+-containing channels to the function of dorsal lateral geniculate thalamocortical relay neurons.

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.

No effect of immunomodulatory therapy in focal epilepsy with positive glutamate receptor type 3--antibodies.

The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans.

Cytoplasmic translocation of Olig2 in adult glial progenitors marks the generation of reactive astrocytes following autoimmune inflammation.

Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes.

The inflamed peripheral nervous system: update on immune therapies.

Immune circuitry in the peripheral nervous system.

The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.

HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation.

HLA-G in the nervous system.

Treatment of active secondary progressive multiple sclerosis with treosulfan.

The genetic influence of the nonclassical MHC molecule HLA-G on multiple sclerosis.

Treatment and treatment trials in multiple sclerosis.

Oral disease-modifying treatments for multiple sclerosis: the story so far.

WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?

Modulation of T-effector function by imatinib at the level of cytokine secretion.

Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G.

Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?

Multiple sclerosis therapy: an update on recently finished trials.

Pharmacological treatment of early multiple sclerosis.

CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing.

The two-pore domain potassium channel TASK3 functionally impacts glioma cell death.

TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions.

B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis.

Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis.

The role of regulatory T cells in multiple sclerosis.

The metalloproteinase-disintegrin ADAM10 is exclusively expressed by type I muscle fibers.

Human myoblasts modulate the function of antigen-presenting cells.

The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation.

A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis.

The trials and errors in MS therapy.

Altered neuronal expression of TASK1 and TASK3 potassium channels in rodent and human autoimmune CNS inflammation.

Effects of natalizumab treatment on Foxp3+ T regulatory cells.

The neuroprotective impact of the leak potassium channel TASK1 on stroke development in mice.

Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions.

The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy.

Idiopathic inflammatory myopathies: current and future therapeutic options.

Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS.

Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.

CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery.

PD-1 regulates neural damage in oligodendroglia-induced inflammation.

Intercellular exchanges of membrane fragments (trogocytosis) between human muscle cells and immune cells: a potential mechanism for the modulation of muscular immune responses.

Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.

Immunomodulatory treatment strategies in multiple sclerosis.

Recent clinical trials and future therapies.

T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible.

Antigen-specific blockade of lethal CD8 T-cell mediated autoimmunity in a mouse model of multiple sclerosis.

The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE.

Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants.

Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies.

CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability.

TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system.

Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss.

Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis.

Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis.

The future of multiple sclerosis therapy.

Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?

Collateral neuronal apoptosis in CNS gray matter during an oligodendrocyte-directed CD8(+) T cell attack.

Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation.

Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death.

Stromal interaction molecules 1 and 2 are key regulators of autoreactive T cell activation in murine autoimmune central nervous system inflammation.

Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve.

Lack of evidence for a pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth disease 1A.

Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice--implications for neuroinflammatory models.

Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation.

The role of dendritic cells in CNS autoimmunity.

Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis.

An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis.

Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis.

B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells.

From the background to the spotlight: TASK channels in pathological conditions.

FOXP3+ T regulatory cells in idiopathic inflammatory myopathies.

Upregulation of K2P5.1 potassium channels in multiple sclerosis.

Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.

Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy.

Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9).

Postpartum disease activity and breastfeeding in multiple sclerosis revisited.

Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies.

Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death.

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.

Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis.

Janus head: the dual role of HLA-G in CNS immunity.

Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis.

Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis.

Active immunization with proteolipid protein (190-209) induces ascending paralysing experimental autoimmune encephalomyelitis in C3H/HeJ mice.

Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.

Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients.

Risks and benefits of multiple sclerosis therapies: need for continual assessment?

Ion channels in autoimmune neurodegeneration.

Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.

Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

Transforming multiple sclerosis trials into practical reality.

Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels.

Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Immunological and clinical consequences of treating a patient with natalizumab.

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.

Rapidly progressive B-cell dominated inflammatory neuropathy and littoral cell angioma of the spleen associated with plasmablastic B-cell lymphoma.

IL-17 silencing does not protect nonobese diabetic mice from autoimmune diabetes.

Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS.

CD4(+) T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid β-related angiitis.

CD4(+) CD25(+) FoxP3(+) regulatory T cells suppress cytotoxicity of CD8(+) effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level.

Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ.

Neuron-directed autoimmunity in the central nervous system: entities, mechanisms, diagnostic clues, and therapeutic options.

Neuroinflammation: the world is not enough.

Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis.

Immune mechanisms of stroke.

Immune therapy of multiple sclerosis--future strategies.

Anti-JC-virus antibody prevalence in a German MS cohort.

Cytotoxic CD8+ T cells and CD138+ plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies.

Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells.

The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis.

Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system.

Identification of two-pore domain potassium channels as potent modulators of osmotic volume regulation in human T lymphocytes.

TRPM2 cation channels modulate T cell effector functions and contribute to autoimmune CNS inflammation.

Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature.

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.

Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.

Dendritic cell vaccination in autoimmune disease.

Correction: Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9).

An assay to quantify species-specific anti-JC virus antibody levels in MS patients.

Thalamic involvement in patients with neurologic impairment due to Shiga toxin 2.

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.

Neurons as targets for T cells in the nervous system.

Monoclonal antibodies in neuroinflammatory diseases.

Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.

Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis.

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.

Rasmussen encephalitis treated with natalizumab.

Con: Regulatory T cells are protective in ischemic stroke.

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS.

Excitotoxic neuronal cell death during an oligodendrocyte-directed CD8+ T cell attack in the CNS gray matter.

Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?

Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis.

DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis.

Correction: Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis.

CD4+NKG2D+ T cells exhibit enhanced migratory and encephalitogenic properties in neuroinflammation.

Evans syndrome associated with sterile inflammation of the central nervous system: a case report.

Specific loss of cellular L-selectin on CD4+ T cells is associated with PML development during HIV infection.

Clinical relevance of brain volume measures in multiple sclerosis.

New evidence for teriflunomide in multiple sclerosis.

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.

The neuroinflammation biobank in the department of neurology, university hospital muenster, Germany.

Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice.

Teriflunomide and its mechanism of action in multiple sclerosis.

Blocking of α4 integrin does not protect from acute ischemic stroke in mice.

Human CD4+ HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo.

Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity.

Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis.

Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers.

Effects of glatiramer acetate in a spontaneous model of autoimmune neuroinflammation.

Response to letter regarding article, "blocking of α4 integrin does not protect from acute ischemic stroke in mice".

VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.

Facing the challenges of chronic pruritus: a report from a multi-disciplinary medical itch centre in Germany.

Apraxia profile differentiates behavioural variant frontotemporal from Alzheimer's dementia in mild disease stages.

Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease.

FoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies.

CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke.

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.

CD3-positive B cells: a storage-dependent phenomenon.

Immunotherapy of multiple sclerosis.

Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking.

Long-term efficacy of alemtuzumab in polymyositis.

Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.

A human post-mortem brain model for the standardization of multi-centre MRI studies.

Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis.

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.

Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.

Fingolimod treatment promotes regulatory phenotype and function of B cells.

Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection").

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration.

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis.

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous system.

The two-pore domain K2 P channel TASK2 drives human NK-cell proliferation and cytolytic function.

Recovery of thalamic microstructural damage after Shiga toxin 2-associated hemolytic-uremic syndrome.

Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells.

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.

Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms.

Trafficking of lymphocytes into the CNS.

Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study.

A novel automated segmentation method for retinal layers in OCT images proves retinal degeneration after optic neuritis.

Optimizing therapy early in multiple sclerosis: An evidence-based view.

B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway.

Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid.

Early and Degressive Putamen Atrophy in Multiple Sclerosis.

PML risk stratification using anti-JCV antibody index and L-selectin.

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Implications of dietary salt intake for multiple sclerosis pathogenesis.

Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer's Dementia Based on Apraxia Profiles.

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.

Case report of bilateral relapsing-remitting sciatic nerve palsy during two pregnancies.

Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.

Sodium chloride promotes pro-inflammatory macrophage polarization thereby aggravating CNS autoimmunity.

The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies.

Impaired Autonomic Responses to Emotional Stimuli in Autoimmune Limbic Encephalitis.

Highlights from the 31st ECTRIMS congress - Barcelona 2015.

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).

CD4(+)HLA-G(+) regulatory T cells: Molecular signature and pathophysiological relevance.

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values.

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis.

ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.

Guidelines on dermatomyositis--excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology.

Immunoadsorption therapy in autoimmune encephalitides.

Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.

CD8(+) T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing.

Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells.

Evidence of a pathogenic role for CD8(+) T cells in anti-GABAB receptor limbic encephalitis.

The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion.

Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets.

The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells.

The quality of cortical network function recovery depends on localization and degree of axonal demyelination.

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.

Shared neural correlates of limb apraxia in early stages of Alzheimer's dementia and behavioural variant frontotemporal dementia.

B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity.

Dichoptic Metacontrast Masking Functions to Infer Transmission Delay in Optic Neuritis.

14-3-3 Proteins regulate K2P 5.1 surface expression on T lymphocytes.

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.

Prothrombin and factor X are elevated in multiple sclerosis patients.

Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS.

Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier.

Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration.

Computed tomography-based quantification of lesion water uptake identifies patients within 4.5 hours of stroke onset: A multicenter observational study.

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.

Diagnostic criteria for Susac syndrome.

Reply to Liu et al.: Haplotype matters: CD226 polymorphism as a potential trigger for impaired immune regulation in multiple sclerosis.

Endothelial Basement Membrane Laminin 511 Contributes to Endothelial Junctional Tightness and Thereby Inhibits Leukocyte Transmigration.

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification.

Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?

Targeting Different Monocyte/Macrophage Subsets Has No Impact on Outcome in Experimental Stroke.